LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Gammadelta T Cells in Cancer Immunotherapy
- 1st Edition - August 1, 2029
- Editors: Ilan Bank, Dieter Kabelitz, Zhinan Yin
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 2 1 8 7 9 - 8
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 1 8 8 0 - 4
Gammadelta T cells in Cancer Immunotherapy shows how the potential of γδ T-cells can effectively be translated into clinical benefit in cancer immunotherapies. With a strong fo… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteGammadelta T cells in Cancer Immunotherapy shows how the potential of γδ T-cells can effectively be translated into clinical benefit in cancer immunotherapies. With a strong focus on finding alternatives to current T cell mediated cancer immunotherapies, the book can also be used as a baseline initial introduction to the field of gamma delta immunotherapy. In 13 chapters, it describes different approaches to a specific model of gammadelta immunotherapy, including ‘delta one T’ (DOT) and Allogeneic CAR. It also describes the rationale for the use of gamma delta cells in immunotherapy, strategies, therapies, and cancer treatment.
Users will find out about the growing interest in the scientific and medical community, while also becoming familiarized with the basic biology of gammadelta T cells, the pre-clinical studies implying their utility in immunotherapy, and with the studies of clinical applications of different forms of gammadelta T cell immunotherapeutic.
- Provides a baseline introduction to the field of gamma delta immunotherapy
- Gives a broad overview of the progress in the field of gamma delta immunotherapy using concrete examples
- Describes an approach to a specific model of gammadelta immunotherapy
- Edited by Ilan Bank, author of the first paper describing the discovery of a novel type of human thymocyte in forming the basis of recognition of the second T cell receptor (gammadelta) and the subsets of T cells expressing these receptors, known now as gammadelta T cells
Researchers and graduate students on cancer research, oncologists, immunologist Clinical researchers, Undergraduate biology students, general libraries, medical students, undergraduate and postgraduate courses in medicine, fellows in oncology and hematology.
1. The rationale for use of gd T cells in immunotherapy.
2. Tissue derived gammadelta T cells as vehicles for cancer immunotherapy
3. DOT-1 gammadelta T cell immunotherapeutic strategies. 4
4. Allogeneic Vg9Vd2 T cells treatment for solid tumors.
5. Gammadelta T cell receptor therapeutic reagents; mechanisms and applications
6. Immunotherapy based on bispecific antibodies targeting Vg9+ gd TCR and tumor antigens.
7. Intratumoral Allogeneic gammadelta T cell therapy for glioblastoma multiforme
8. Allogeneic CAR expressing Vd1+ gammadelta T cells for lymphoma and hepatocellular carcinoma
9. Activating Monoclonal antibodies directed against butyrophilin ligands of Vg9Vd2+ gammadelta T cells for cancer immunotherapy
10. Pro tumoral gammadelta T cells and their implication for immunotherapy.
11. Overcoming hurdles of gammadelta T cell immunotherapeutics
12. Increasing efficacy of gammadelta immunotherapy by targeted modulation of tumor phosphoantigens.
13. Summary and conclusions
2. Tissue derived gammadelta T cells as vehicles for cancer immunotherapy
3. DOT-1 gammadelta T cell immunotherapeutic strategies. 4
4. Allogeneic Vg9Vd2 T cells treatment for solid tumors.
5. Gammadelta T cell receptor therapeutic reagents; mechanisms and applications
6. Immunotherapy based on bispecific antibodies targeting Vg9+ gd TCR and tumor antigens.
7. Intratumoral Allogeneic gammadelta T cell therapy for glioblastoma multiforme
8. Allogeneic CAR expressing Vd1+ gammadelta T cells for lymphoma and hepatocellular carcinoma
9. Activating Monoclonal antibodies directed against butyrophilin ligands of Vg9Vd2+ gammadelta T cells for cancer immunotherapy
10. Pro tumoral gammadelta T cells and their implication for immunotherapy.
11. Overcoming hurdles of gammadelta T cell immunotherapeutics
12. Increasing efficacy of gammadelta immunotherapy by targeted modulation of tumor phosphoantigens.
13. Summary and conclusions
- No. of pages: 216
- Language: English
- Edition: 1
- Published: August 1, 2029
- Imprint: Academic Press
- Hardback ISBN: 9780443218798
- eBook ISBN: 9780443218804
IB
Ilan Bank
Dr. Bank is a physician and immunologist, involved in research in the field of gammadelta T cells since 1986 . His scientific career henceforth included studies contributing to definition of the role of gammadelta T cells in autoimmune, infectious and malignant conditions in humans. Regarding the latter, his laboratory was among the first to show anti breast cancer activity of human gammadelta T cells, and later also their mechanisms of activity against glioblastoma. Most recently, his group participated in creation of anti lymphoma CAR (anti CD20) bearing human gammadelta T cells and reported preclinical efficacy., He has been editor of a topic on Gammadelta T cells in cancer including 11 papers published in Frontiers of Immunology and an active participant and organizer in the biannual gammadelta T cell meetings, and has been invited to chair the immunotherapy session in the upcoming meeting in Lisbon , 2023
Affiliations and expertise
Department of Medicine, Rheumatology Unit, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, IsraelDK
Dieter Kabelitz
Dieter Kabelitz is full professor at the University of Kiel, Germany, and Director of the Institute of Immunology. Dieter Kabelitz studied medicine in Freiburg and Munich, Germany. He was a post-doc in Uppsala/Sweden and at Rockefeller University, New York. In 1988, he was appointed Associate Professor for Cellular Immunology at the University of Heidelberg. From 1992 to 1999 he was Head of the Department of Immunology at the Paul-Ehrlich Institute in Langen, Germany. Since 1999 he is a full professor at the University of Kiel and Director of the Institute of Immunology. His scientific expertise is in the field of the functional characterization of human T cells with a special focus on T cells. Current projects aim to explore the potential of human T cells for the immunotherapy of cancer. He has published more than 360 papers listed in PubMed/Medline. Dieter Kabelitz was chairman of the Collaborative Research Center (SFB) 415 „Specificity and Pathophysiology of Signal Transduction Pathways“ funded at Kiel University by the German Research Foundation (DFG). He is a founding member and member of the Steering Committee of the DFG-funded Cluster of Excellence „Inflammation-at-Interfaces“. He was President of the German Society for Immunology (DGfI) in 2011 and 2012, and he is a Council member of the International Union of Immunological Societies (IUIS) and chair of the Education Committee (EDU) of IUIS.
Affiliations and expertise
Institute of Immunology, Christian-Albrechts-University, Kiel, Germany